Immix Biopharma, INC 8-K filings

Immix Biopharma, Inc. announced the termination of Richard Graydon as an officer of the company, effective July 17, 2026.

Immix Biopharma stockholders re-elected all director nominees and ratified the appointment of Crowe LLP as independent auditors.

Immix Biopharma has priced an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share to raise $150 million in gross proceeds.

Immix Biopharma announced a 95% complete response rate in its Phase 2 NEXICART-2 trial for AL Amyloidosis, with all MRD-negative patients achieving CR.

Immix Biopharma announced the completion of enrollment for its NEXICART-2 clinical trial for NXC-201, with topline results anticipated in Q3 2026, paving the way for a Biologics License Application submission and commercial launch.

Immix Biopharma, Inc. amended its At The Market offering agreement to allow for the sale of up to $100 million in common stock.

Immix Biopharma, Inc. announced an underwritten public offering of common stock and pre-funded warrants, expected to raise approximately $93.7 million in net proceeds.

Immix Biopharma announced positive Phase 2 NXC-201 results for relapsed/refractory AL Amyloidosis, achieving a 75% complete response rate in the NEXICART-2 trial.

Immix Biopharma, Inc. filed an 8-K to include newly dated consents from its independent registered public accounting firms for its Form S-3 Registration Statement.

Immix Biopharma, Inc. announced a private placement raising approximately $9.1 million and the appointment of Dr. Nancy Chang to its Board of Directors, strengthening its financial position and governance.

Immix Biopharma, Inc. announced that its stockholders approved all proposals at the 2025 Annual Meeting, including the election of eight directors and the ratification of Crowe LLP as the independent registered public accounting firm.

Immix Biopharma, Inc. has entered into an At The Market Offering Agreement with Citizens JMP Securities, LLC to potentially sell up to $50 million of its common stock, providing a flexible capital raising mechanism.

Immix Biopharma's subsidiary, Nexcella, has received an $8 million grant from the California Institute for Regenerative Medicine to advance the clinical development of its CAR-T therapy, NXC-201, for relapsed/refractory AL Amyloidosis.

Immix Biopharma has changed its independent registered public accounting firm from KMJ Corbin & Company LLP to Crowe LLP, effective July 17, 2024.

Immix Biopharma stockholders approved amendments to the company's 2021 Omnibus Equity Incentive Plan, increasing the share reserve and adopting an evergreen provision.

Immix Biopharma has successfully merged with its majority-owned subsidiary, Nexcella, Inc., making Nexcella a wholly-owned subsidiary.

Immix Biopharma has priced a public offering of 5,535,055 shares of common stock at $2.71 per share, expecting gross proceeds of $15 million.

Immix Biopharma has suspended the offering of its common stock under a sales agreement with ThinkEquity LLC, pending the filing of a new prospectus supplement with the SEC.